A role for IFN-λ1 in multiple myeloma B cell growth

被引:23
作者
Novak, A. J. [1 ]
Grote, D. M. [1 ]
Ziesmer, S. C. [1 ]
Rajkumar, V. [1 ]
Doyle, S. E. [2 ]
Ansell, S. M. [1 ]
机构
[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA
[2] Zymogenet Inc, Dept Hematol & Oncol, Seattle, WA 98105 USA
基金
美国国家卫生研究院;
关键词
myeloma; IL-29; IFN-lambda;
D O I
10.1038/leu.2008.263
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Multiple myeloma (MM) is a progressive disease that results from dysregulated proliferation of plasma cells. Although, causative factors such as genetic events and altered expression of anti-apoptotic factors have been described in a number of patients, the mechanistic details that drive myeloma development and continued growth of malignant cells remain largely undefined. Numerous growth factors, including interleukin (IL)-6, Insulin-like growth factor-1 and IL-10 have been shown to promote growth of MM cells suggesting a significant role for cytokines in this disease. Interferon (IFN)-lambda 1 is a new member of the Class II cytokine family that, similar to IFN-alpha, has been shown to mediate viral immunity. In light of data supporting a role for cytokines in myeloma, we investigated the significance of IFN-lambda 1 on myeloma cell biology. Our studies show for the first time that myeloma cells bind to soluble IFN-lambda 1, and that IFN-lambda 1 induces myeloma cell growth and protects against dexamethasone-induced cell death. Our data also show that IFN-lambda 1 induces phosphorylation of STAT1, STAT3 and Erk. Taken together, our results suggest that IFN-lambda 1 may regulate myeloma cell biology and could prove to be therapeutically important.
引用
收藏
页码:2240 / 2246
页数:7
相关论文
共 16 条
[1]
DEVELOPMENT OF AGGRESSIVE PLASMA-CELL LEUKEMIA UNDER INTERFERON-ALPHA THERAPY [J].
BLADE, J ;
LOPEZGUILLERMO, A ;
TASSIES, D ;
MONTSERRAT, E ;
ROZMAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (03) :523-525
[2]
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression [J].
Brand, S ;
Beigel, F ;
Olszak, T ;
Zitzmann, K ;
Eichhorst, ST ;
Otte, JM ;
Diebold, J ;
Diepolder, H ;
Adler, B ;
Auernhammer, CJ ;
Göke, B ;
Dambacher, J .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2005, 289 (05) :G960-G968
[3]
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1 -: Similarities with type I interferon signaling [J].
Dumoutier, L ;
Tounsi, A ;
Michiels, T ;
Sommereyns, C ;
Kotenko, SV ;
Renauld, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (31) :32269-32274
[4]
Transactivation of gp130 in myeloma cells [J].
French, JD ;
Walters, DK ;
Jelinek, DF .
JOURNAL OF IMMUNOLOGY, 2003, 170 (07) :3717-3723
[5]
Differential human multiple myeloma cell line responsiveness to interferon-alpha - Analysis of transcription factor activation and interleukin 6 receptor expression [J].
Jelinek, DF ;
AagaardTillery, KM ;
Arendt, BK ;
Arora, T ;
Tschumper, RC ;
Westendorf, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) :447-456
[6]
Jelinek DF, 1997, CURR TOP MICROBIOL, V224, P261
[7]
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex [J].
Kotenko, SV ;
Gallagher, G ;
Baurin, VV ;
Lewis-Antes, A ;
Shen, ML ;
Shah, NK ;
Langer, JA ;
Sheikh, F ;
Dickensheets, H ;
Donnelly, RP .
NATURE IMMUNOLOGY, 2003, 4 (01) :69-77
[8]
INTERLEUKIN-10 IS A PROLIFERATION FACTOR BUT NOT A DIFFERENTIATION FACTOR FOR HUMAN MYELOMA CELLS [J].
LU, ZY ;
ZHANG, XG ;
RODRIGUEZ, C ;
WIJDENES, J ;
GU, ZJ ;
MORELFOURNIER, B ;
HAROUSSEAU, JL ;
BATAILLE, R ;
ROSSI, JF ;
KLEIN, B .
BLOOD, 1995, 85 (09) :2521-2527
[9]
Biological activity of interleukins-28 and-29: Comparison with type I interferons [J].
Meager, A ;
Visvalingam, K ;
Dilger, P ;
Bryan, D ;
Wadhwa, M .
CYTOKINE, 2005, 31 (02) :109-118
[10]
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival [J].
Novak, AJ ;
Darce, JR ;
Arendt, BK ;
Harder, B ;
Henderson, K ;
Kindsvogel, W ;
Gross, JA ;
Greipp, PR ;
Jelinek, DF .
BLOOD, 2004, 103 (02) :689-694